Keros Therapeutics, Inc.
KROS
$11.58
$0.110.96%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 684.02% | 948.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 684.02% | 948.65% | |||
| Cost of Revenue | -322.86% | 21.50% | |||
| Gross Profit | 330.86% | -20.65% | |||
| SG&A Expenses | 8.60% | -1.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.66% | 16.98% | |||
| Operating Income | 9.21% | -16.29% | |||
| Income Before Tax | 13.65% | -17.01% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 13.09% | -17.01% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.09% | -17.01% | |||
| EBIT | 9.21% | -16.29% | |||
| EBITDA | 9.29% | -16.38% | |||
| EPS Basic | 19.01% | -12.39% | |||
| Normalized Basic EPS | 19.53% | -12.38% | |||
| EPS Diluted | 59.52% | -124.87% | |||
| Normalized Diluted EPS | 19.53% | -12.38% | |||
| Average Basic Shares Outstanding | 7.31% | 4.12% | |||
| Average Diluted Shares Outstanding | 7.31% | 4.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
